Clinical Trials Logo

Polio clinical trials

View clinical trials related to Polio.

Filter by:

NCT ID: NCT00315055 Completed - Hepatitis B Clinical Trials

Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule

Start date: July 2006
Phase: Phase 3
Study type: Interventional

To demonstrate that the immune response to hepatitis B antigen of the DTaP-IPV-Hep B-PRP~T is non-inferior to that of the association of PENTAXIM™ and ENGERIX B® one month after a three dose (2-3-4 month) primary series. Immunogenicity - To assess pre- and post-primary series - To assess pre- and post-booster series.

NCT ID: NCT00259337 Completed - Tetanus Clinical Trials

Immunogenicity and Safety of Pentaxim™ in an Indian Population

Start date: February 2006
Phase: Phase 3
Study type: Interventional

The present clinical study will assess the immunogenicity as the primary objective and the reactogenicity as the secondary objective of Aventis Pasteur's DTacP-IPV// PRP~T combined vaccine (Pentavac™ or Pentaxim™) as a three-dose primary vaccination at 6, 10 and 14 weeks of age followed by a booster dose during the second year of life. Safety: This study will describe the safety after each dose of the primary series of the study's combined vaccine (Pentaxim™).

NCT ID: NCT00255047 Completed - Diphtheria Clinical Trials

Safety and Immune Response of Different Pediatric Combination Vaccines.

Start date: November 2005
Phase: Phase 3
Study type: Interventional

The overall aim of the study is to corroborate that a schedule consisting of 3 doses of Pentacel™ and a 4th dose of DAPTACEL® and ActHIB® or 4 doses of Pentacel™ or 4 doses of Quadracel and ActHIB® is as safe and immunogenic as a standard of care schedule based on 3 doses of the licensed-equivalent vaccines DAPTACEL®, Vero cell derived Inactivated Poliovirus vaccine (IPOL®), and ActHIB® and a 4th dose of DAPTACEL® and ActHIB®.

NCT ID: NCT00254917 Completed - Tetanus Clinical Trials

Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines

Start date: October 2003
Phase: Phase 4
Study type: Interventional

The present clinical study will assess the immunogenicity and reactogenicity of the subsequent administration of Aventis Pasteur's DTacP-IPV//PRP~T combined vaccine (PENTAVAC™/PENTAXIM), as a three-dose primary vaccination in 6, 10 and 14 weeks of age schedule followed by a booster vaccination during the second year of life with the aim to cover the WHO EPI primary vaccination schedule at this age for diphtheria, tetanus, pertussis, poliomyelitis and Hib vaccines. WHO EPI vaccination schedules for hepatitis B (either 0, 6 and 14 weeks or 6, 10 and 14 weeks of age) will be also assessed in infants born to HBsAg seronegative mothers. To assess the safety of Pentaxim.